Cardiac Effects of a Single Dose of Pimobendan in Cats With Hypertrophic Cardiomyopathy; A Randomized, Placebo-Controlled, Crossover Study

Oldach, Maureen S.; Ueda, Yuichi; Ontiveros, Eric S.; Fousse, Samantha L.; Harris, Samantha P.; Stern, Joshua A.

doi:10.3389/fvets.2019.00015

Cited by 26 publications

(44 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effect of pimobendan on LA function in cats, both healthy and with hypertrophic cardiomyopathy, has been recently reported, with conflicting results (Kent, 2011;Oldach et al, 2019). A single oral dose of pimobendan was found to increase LA FS in cats with asymptomatic hypertrophic cardiomyopathy (Oldach et al, 2019). In contrast, in healthy cats, pimobendan was reported to reduce LA end-diastolic size but with minimal effect on LA functional indices, following oral treatment for 7 days (Kent, 2011).…”

Section: Results Of This Study Indicate That 2d (Diameter and Volume mentioning

confidence: 99%

“…Although it is known to reduce LV diameters in systole and diastole and improve systolic and diastolic function (Suzuki et al, 2011;Boswood et al, 2016), the effect of pimobendan on LA mechanical phasic function in dogs affected by MMVD has not been studied despite the well-recognized importance of the contribution of atrial contraction to ventricular filling (Nakamura et al, 2014). Furthermore, conflicting results on the effect of this drug on cats' LA function have been reported (Kent, 2011;Oldach et al, 2019). The aim of this investigation was to study the effects of pimobendan on LA function in dogs with preclinical MMVD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease

et al. 2020

View full text Add to dashboard Cite

Background: Left atrial (LA) function is an important determinant of the left ventricular (LV) filling, playing a key role in maintaining optimal cardiac performance. Pimobendan is a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. The present study aims to investigate the effects of pimobendan on LA function in dogs with stage B2 myxomatous mitral valve disease (MMVD). Aim: The aim of this investigation was to study the effects of pimobendan on LA function in dogs with preclinical MMVD. Methods: Twenty-seven dogs with stage B2 MMVD were retrospectively included. LA function was assessed before and 1-6 months following pimobendan initiation. For each dog, two-dimensional (2D) echocardiography was performed to assess LA diameter and volume for each phase of the LA cycle and to assess complete, passive, and active LA function. Pulsed-wave tissue Doppler imaging (TDI) of the left ventricular longitudinal myocardial velocity associated with atrial contraction (A'), both at the level of the interventricular septum and the LV free wall, was also used as an indicator of LA function. Results: There were no significant differences in any of the left atrial variables pre-and posttreatment. Conclusion: Echocardiographic estimates of LA function by 2D diameters and volumes and TDI A' in dogs with MMVD do not change after treatment with pimobendan.

show abstract

Section: Results Of This Study Indicate That 2d (Diameter and Volume mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…За останні кілька років ветеринарна медицина зробила істотний ривок вперед. Особливо в області діагностики, яка дозволяє не допустити розвиток серйозних патологій у тварин (Varkholiak, 2016;Brett et al, 2019;Oldach et al, 2019). Кардіологія це один із напрямків ветеринарної медицини, який найбільш інтенсивно розвивається.…”

Section: вступunclassified

Determination of the chronic toxicity of preparation “Bendamin” on laboratory animals

Varcholyak¹,

Гутый²

2019

TAVM

View full text Add to dashboard Cite

In the process of creating and introducing each new preparation one of the stages is its toxicological studies with the clarification of the parameters of acute and chronic toxicity in white rats in the long term of its intragastric introduction. The aim of the work was to determine the parameters of the chronic toxicity of the cardiological preparation "Bendamin" on laboratory animals in a laboratory experiment. The studies were carried out on white, sexually-mature, young male rats of the Vistar line of 2-3 months old, weighing 170-185 g, which were kept on a standard ration of the Institute Vivarium of the State Scientific-Research Control Institute of Veterinary Preparations and Feed Additives. Four experimental groups of white rats were formed. The first experimental group served as a control. Other experimental groups were prescribed "Bendamin", respectively, in therapeutic, 5-fold and 10-fold doses. The preparation in the above doses was given at a specific time, daily, during 30 days, peroral, fasting, using a probe for laboratory animals. During the research period to determine the chronic toxicity of "Bendamin", no probable changes in the behavior of the experimental animals were observed. It should be noted the slight inhibition of the organism state of the being studied group of rats receiving a 10-fold dose of the preparation. In the investigated group of rats, which was injected the preparation in the 10-fold dose, inhibition of protein synthesis and detoxification function of the liver was established. There is also a violation of the functional state of the liver, which indicates an increase in the activity of aminotransferases in their blood. In the study of the relative weight coefficients of the mass of the internal organs, it was found that the introduction of the "Bendamin" preparation in the 10-fold dose led to a significant change in the relative weight of the liver and the spleen. The "Bendamin" preparation in the therapeutic and 5-fold doses contributed to a slight increase in the weighting coefficient. Lung weight loss occurred at introduction of the preparation in the 5-and 10-fold doses. According to State Standard 12.1.007-76, "Bendamin", for intragastric introduction, according to the degree of hazard belongs to the fourth-class toxicity-low toxicity substances (DL 50 more than 50,000 mg/kg body weight).

show abstract

“…Annually, a large number of new investigations are conducted in the world, based on the results of which refine the views on the treatment of cardiovascular diseases (Varkholiak & Gutyj, 2018). Recently, our ideas about the pathogenetic mechanisms of heart failure have changed significantly, and new approaches to its therapy are being developed (Tjostheim et al, 2019;Oldach et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

The influence of the preparation “Bendamin” on the morphological and biochemical indices of blood of rats in experimental modeling of heart failure

Varkholiak¹,

Gutyj²

2020

Ukr. Jour. of Vet. and Agr. Sci.

View full text Add to dashboard Cite

The purpose of this work was to study the influence of “Bendamin” on the morphological and biochemical indices of rat blood in experimental modeling of heart failure. The investigation were performed on white sexually mature young male-rats of Wistar line weighing 180–200 g, kept at the standard ration of the institute vivarium of the State Research Institute of Veterinary Preparations and Fodder Additives. To create a model of doxorubicin-induced cardiomyopathy, 24 male rats were selected. Animals were divided into 3 groups of 6 animals in each: control group – intact animals; experimental group E1, in which animals were modeled doxorubicin-induced cardiomyopathy by intraperitoneal injected of doxorubicin at a dose of 2.5 mg/kg 3 times a week for two weeks; experimental group E2, in which animals, after injection of doxorubicin, the preparation “Bendamin” was injected in the dose 20 mg/kg intragastrically. For experimental modeling of heart a decrease in the number of red blood cells was found in the blood of rats of the first experimental group by 34.7 % and hemoglobin level – by 24.2 %, with a simultaneous increase in the average hemoglobin content in one erythrocyte by 16.2 %. Doxorubicin-induced cardiomyopathy in rats of the first experimental group was accompanied by a decrease in leukocyte count by 22.2 %, an increase in uric acid level by almost in 2 times, creatinine by 11.4 %, cholesterol by 61.1 %. In the research of the protein synthesizing function of the liver of rats in experimental modeling of heart failure, a decrease in total protein by 9.6 % was found. These changes were accompanied by a slight decrease in albumin levels and a slight increase in globulin levels. By intoxication with doxorubicin, rats of the first experimental group showed a violation of the functional state of the liver, indicating an increase in the activity of aminotransferases in their blood, namely: AlAT by 34.2 %, AsAT – by 21.7 %, accordingly. Positive action of cardio preparation “Bendamin” on rats organism under conditions of creation of a model of doxorubicin-induced cardiomyopathy was installed, manifested by the normalization of hematological and biochemical parameters, functional status and protein synthesis of the liver.

show abstract

Cardiac Effects of a Single Dose of Pimobendan in Cats With Hypertrophic Cardiomyopathy; A Randomized, Placebo-Controlled, Crossover Study

Cited by 26 publications

References 28 publications

Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease

Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease

Determination of the chronic toxicity of preparation “Bendamin” on laboratory animals

The influence of the preparation “Bendamin” on the morphological and biochemical indices of blood of rats in experimental modeling of heart failure

Contact Info

Product

Resources

About